News Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Real-time BOERSE MUENCHEN Other stock markets 14:13:52 2024-07-01 EDT			5-day change	1st Jan Change
4.52 ^EUR	0.00%		+7.11%	-14.72%

12:26pm	Akeso, Inc. Announces Change of Directors	CI
06-04	Akeso Expands Territory of License Agreement for Lung Cancer Drug	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akeso, Inc. Announces Change of Directors	06:26am	CI
Akeso Expands Territory of License Agreement for Lung Cancer Drug	06-04	MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	06-03	CI
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15%	05-30	MT
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF)	05-30	CI
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival	05-30	CI
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut	05-24	MT
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%	05-24	MT
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection	05-24	CI
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	04-24	MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	04-23	CI
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	03-25	AQ
Akeso to Raise Over HK$1 Billion Via Share Sale	03-22	MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast	03-18	MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC	03-06	CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5%	03-05	MT
Akeso, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	03-04	CI
Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy	02-23	MT
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	02-15	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Akeso, Inc. BOERSE MUENCHEN

Equities

4RY

KYG0146B1032

Summary

Filters